Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

DSIP

Delta Sleep-Inducing Peptide

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

DSIP is a 1970s Schoenenberger-Monnier nonapeptide whose namesake sleep-promoting role was never robustly confirmed. Human data are sparse, old, and inconsistent: small studies such as Schneider-Helmert's IV infusion work (six volunteers) and a controlled insomnia trial reported modest or delayed effects, while other studies found no correlation between DSIP and slow-wave sleep, and review articles (Graf & Kastin) conclude the peptide never clarified sleep mechanisms. It remains an unapproved research chemical sold for sleep, so the supported human sleep claim grades at 1.

Counted on the record: 3 human studies, 1 randomized trial, 0 animal studies, 0 lab studies.

One randomized controlled study is recorded. Human-study and participant totals remain null because cohorts may overlap.

FDA
Not FDA approved. Nominated to the Section 503A bulk drug substances list as Emideltide (DSIP); scheduled for Pharmacy Compounding Advisory Committee review July 23-24, 2026, for opioid withdrawal, chronic insomnia, and narcolepsy. Review only, not an approval.
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Sparse, dated, and inconsistent human data; very short half-life; sold as a research chemical with no established long-term safety.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about DSIP. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A nonapeptide isolated in the mid-1970s by the Schoenenberger-Monnier group from the cerebral venous blood of rabbits in induced sleep, and named for the delta (slow-wave) sleep it appeared to promote. Despite the name, that sleep-promoting role was never robustly confirmed, and the human evidence stays sparse, old, and inconsistent. It is sold as an unapproved research chemical for sleep and is now under FDA advisory-committee review under the name Emideltide, which is a compounding review rather than an approval.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Deep-sleep induction
  • Stress reduction

How it is supposed to work

DSIP has the most promising name in this entire library, Delta Sleep-Inducing Peptide, and almost nothing to back it up. It was found in 1977 in the blood of sleeping rabbits and named because it seemed to increase the deep, slow delta brain waves of restorative sleep. The hope was that it might be the body’s own natural sleep switch. The problem is that nearly fifty years later, nobody has actually shown how, or even reliably whether, it works. Its mechanism is unknown, and it is sold for sleep mostly on the strength of that name.

  1. Step 1Delta sleep wavesResearchers found DSIP in sleeping rabbits in 1977 and named it for the deep slow brain waves it seemed to increase.
  2. Step 2ReceptorResearchers have yet to identify a receptor or a pathway for it, so the mechanism stays unknown.

A small peptide of nine amino acids.

Type
Nonapeptide
Named for
Delta-wave sleep
Mechanism
Unknown
Evidence
Thin, conflicting
Use
Gray-market sleep
Approved
No

The Perfect Name For Sleep, On Almost No Evidence

DSIP is a cautionary tale about how far a good name can travel ahead of the evidence. Isolated in 1977 and christened for inducing deep delta-wave sleep, it was an obvious candidate for the body’s natural sleep factor, and that promise has powered its gray-market sale for sleep ever since. But the science never delivered. One review flatly called it an unresolved riddle, noting that the link between DSIP and sleep has never been properly characterized, in part because no one has clearly isolated its gene or its receptor. The human data is thin and contradictory: a single study of sleep brain-waves in healthy men found only minor effects, and insomnia studies returned conflicting results, with at best modest improvements. The most careful descriptions call it a gentle sleep-promoter rather than a sedative, more active when sleep is already disturbed and barely noticeable in healthy people, which is a long way from the knockout the name implies. It is not approved anywhere, its mechanism is genuinely unknown, and there is no human safety data for injecting it.

How it is taken

  • Injection

    solution Synthetic DSIP in an intravenous research preparation. The clinical abstracts do not establish vial, reconstitution, or storage stability. Small human sleep experiments in the early 1980s.

  • Research

    lyophilized white research powder DSIP reported as greater than 99% pure; a separate laboratory stock used potassium-phosphate buffer. The patent describes preparation and protease testing, not a validated finished-product shelf life. Patent synthesis and protein-complex experiments.

Safety in detail

  • We hold sparse and dated human data, mostly from small studies of sleep in healthy men.
  • Researchers have yet to identify its receptor, so its effects and interactions stay unpredictable.

Children and teenagers

DSIP is an unapproved sleep peptide with an unknown mechanism and no human safety data, which makes it inappropriate for minors. Pediatric sleep problems belong with pediatricians, starting with behavioral approaches. There is no appropriate pediatric use.

What people get wrong

  • Often saidThe name means DSIP reliably produces deep sleep

    ActuallyThe name came from early rabbit EEG experiments. The human studies were tiny, produced mixed or modest results, and never established DSIP as a reliable sleep treatment.

  • Often saidDSIP is a modern, well-tested sleep medicine

    ActuallyThe main human reports involved only six or seven people and were published in the early 1980s. Its receptor and reproducible mechanism remain unknown.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

DSIP’s money runs through gray-market peptide vendors and research-reagent suppliers selling it as a powder, feeding the sleep-biohacking market. There is no approved product. The marketing rests on the evocative name, the delta-wave origin story and a couple of dated studies, rather than on any solid evidence.

How we got here

DSIP was isolated in the mid-1970s by the Swiss Schoenenberger-Monnier group from the cerebral venous blood of rabbits placed in an electrically induced sleep state, and was named for the delta (slow-wave) sleep it appeared to promote. The nine-amino-acid sequence was characterized as WAGGDASGE, yet no mammalian gene encoding it has been identified and its endogenous role stayed unclear. It was studied in the Soviet and Russian literature as the preparation Deltaran for uses beyond sleep, and today circulates mainly as a research chemical sold as DSIP or DSIP acetate for sleep. In the United States it now appears in FDA regulatory documents under the name Emideltide, nominated to the Section 503A bulk drug substances list and scheduled for a Pharmacy Compounding Advisory Committee review on July 23-24, 2026, which is a compounding review rather than a drug approval.

DSIP was isolated in 1977 by Swiss researchers from the brain blood of sleeping rabbits and named for the deep delta-wave sleep it appeared to promote, making it an obvious candidate for the body’s natural sleep factor. Decades of study failed to characterize that sleep link or to isolate its gene or receptor, and human studies returned conflicting, modest results. A later review labeled it an unresolved riddle, yet it persists as a gray-market sleep peptide sold largely on the strength of its name.

Discovery

1977 to 1977

The peptide was named from a rabbit EEG experiment.

  1. 1977DSIP is isolated, sequenced, and namedSynthetic DSIP increased delta and spindle EEG patterns after direct brain infusion in rabbits. The name came from this animal result.

Small human studies

1981 to 1984

Tiny sleep studies produced suggestive but inconsistent findings.

  1. 1981DSIP is tested in chronic insomniaIntravenous DSIP was associated with longer, less interrupted sleep in six people, but the sample was too small for a reliable treatment conclusion.
  2. 1984An uncontrolled insomnia series reports improvementSeven people received ten injections. Without a control group, the report cannot separate treatment effects from expectation, natural change, or other care.

The numbers behind the grade

Type
Nonapeptide
Named for
Delta sleep
Mechanism
Unknown
Evidence
Thin
Use
Gray-market sleep
Approved
No

The people taking it

Users are people with poor sleep, especially those who have already tried other things, alongside sleep-focused biohackers. The draw is the name, which promises deep sleep.

The peptide with the most promising sleep name and almost no evidence to match, a 1977 delta-sleep candidate that remains an unresolved riddle, sold gray-market for insomnia on its name rather than data.

DSIP’s users are people with insomnia or poor sleep, especially the treatment-resistant who are drawn by the natural-sleep-factor pitch, along with sleep-focused biohackers and stress and recovery seekers. It appeals to people desperate enough for sleep to try an unproven compound.

A gray-market sleep and insomnia peptide marketed on its evocative name and delta-wave-sleep origin, with thin, conflicting human evidence and an unknown mechanism. Not approved.

Set against the alternatives

Against real sleep aids, melatonin, the prescription Z-drugs and the newer orexin-blocking drugs, which have actual trial evidence and, for the drugs, approval, DSIP has a riddle. Against other gray-market sleep and recovery peptides and the wider sleep-biohacking market, it is among the most marketed and least evidenced. And against the broader pattern of evocative naming, it is the prime example of an appealing name, Delta Sleep-Inducing Peptide, doing the work that data should. Its strength is its name; its weakness is everything behind it.

What we do not know

  • Whether DSIP, or a DSIP-like peptide, has any real, reproducible sleep effect.
  • What its actual mechanism and receptor are, still unidentified.
  • Whether its proposed stress-axis and modulatory effects are genuine.
  • Why such a promising candidate never panned out.

What could change

Open mechanismIt remains an unsolved mechanistic puzzle still drawing study.DSIP-like peptideSome researchers propose a related molecule explains its activity.No real developmentThere is no genuine therapeutic development pipeline.Evidence-based contrastIt stands against the real evidence in sleep medicine.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available only through gray-market research vendors, which is not a human-use route and offers no approval, no human safety data, an unknown mechanism and thin, conflicting evidence. There is no legitimate route. For sleep problems, evidence-based approaches like sleep hygiene, cognitive behavioral therapy for insomnia and approved options under a clinician vastly outclass an unproven peptide sold on its name. The name is not evidence.

Gray-market and research-grade DSIP is moderately priced, and the cost buys an unproven compound rather than a validated sleep treatment.

Synthesized overseas, mainly in China, as fragile gray-market or research-use-only powder, with no human-grade quality assurance.

China and research vendorsSupply gray-market and research-use-only powder.Fragile compoundThe peptide is unstable and needs careful storage and handling.No approved supplyThere is no regulated, human-grade source.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about DSIP.

Nothing outstanding on this one.

Sources

The studies that matter

  • Discovery1977

    DSIP was isolated from the brain blood of sleeping rabbits and named for increasing deep delta-wave EEG activity.

  • Unknown mechanismongoing

    No clear gene or receptor has been identified; proposed GABA, opioid and stress-axis effects remain unconfirmed.

  • Human sleep datalimited

    One study of sleep brain-waves in healthy men found only minor effects, and insomnia studies gave conflicting, modest results.

  • Modulator, not sedativereviews

    Careful descriptions cast it as a gentle sleep-promoter, more active when sleep is disturbed and minimal in healthy people.

  • Unresolved riddlereview

    Decades on, a review concluded the link between DSIP and sleep has never been characterized and remains weak.